But before you buy a dividend stock ETF, it's important to review its holdings and understand why it's a good choice for your ...

The U.S. Food and Drug Administration has approved Hepcludex (bulevirtide‐gmod) injection to treat chronic hepatitis delta ...

Quick ReadA $1.1 million portfolio split across HDV, MUB, O, SPYI, and SGOV targets a 4.8% yield generating $52,800 annually ...

Explore how sector allocations and volatility profiles set these two dividend ETFs apart for investors seeking income with different risk appetites.

Hepcludex is now the first and only approved treatment for HDV patients in the US, marking a significant milestone for HDV ...

Combination tobevibart 300 mg + elebsiran 200 mg q4w achieved HDV RNA TND in 77% at week 72 and 88% at week 96, outperforming tobevibart monotherapy. Profound HBsAg lowering occurred with dual therapy ...

FDA approves 1st chronic HDV treatment Hepcludex to reduce virus levels and improve liver function in adults with hepatitis delta virus.

HDV charges a marginally higher expense ratio than SCHD but has outperformed over the past year. SCHD offers a higher dividend yield and greater diversification across its 101 holdings. Both funds ...

Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the ...

The Vanguard High Dividend Yield ETF (VYM) and the iShares Core High Dividend ETF (HDV) both provide exposure to U.S. dividend equities, but their income profiles are built differently. For investors ...